• Nanion Technologies: イオンチャネル研究のスマートツール

    Nanion Technologies: イオンチャネル研究のスマートツール

  • CardioExcyte 96 SOL: 心筋の光ペーシング

    CardioExcyte 96 SOL: 心筋の光ペーシング

  • SURFE²R 96SE: ラベルフリーのトランスポーターHTS

    SURFE²R 96SE: ラベルフリーのトランスポーターHTS

  • 脂質二分子膜実験: Orbitシリーズ

    脂質二分子膜実験: Orbitシリーズ

Our Product Portfolio

SyncroPatch 384i

SyncroPatch 384i

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16

Orbit 16

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

hERG - "Characterization of hERG (HEK293) on Nanion's Port-a-Patch"

icon pap   Port-a-Patch application note:   logo pdf   (0.7 MB)
Cells were kindly provided by Millipore.  

Summary:

The hERG gene (KCNH2) encodes a potassium ion channel responsible for the repolarizing IKr current in the cardiac action potential (Sanguinetti et al., 1995). Abnormalities in this channel may lead to either Long QT Syndrome (LQT2) (with loss-of-function mutations) or Short QT syndrome (with gain-of-function mutations), both potentially fatal cardiac arrhythmia, due to repolarization disturbances of the cardiac action potential. Given the importance of this channel in maintaining cardiac function, it has become an important target in compound safety screening. A large range of therapeutic agents with diverse chemical structures have been reported to induce long QT syndrome. These include antihistamines (e.g. terfenadine), gastrointestinal prokinetic agents (e.g. cisapride) and others. In this report we present data that were collected on the Port-a-Patch. Cells (HEK293 stably expressing hERG, supplied by Millipore) were tested. Current amplitudes, IVs and cisapride as well as quinidine dose-response curves were analyzed.

Back

Nanion コーポレートブログ

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok